Bupropion HCl
Phase 1Small molecule
NovartisBupropion HCl is one of 46 small molecule programs targeting Obesity. It is currently in Phase 1.
1
Indications
5
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Maridebart Cafraglutide
AmgenPhase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
Cagrisema
Novo NordiskPhase 3
Eloralintide
Eli LillyPhase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fasting Conditions2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bupropion HCl. EMBL-EBI & Wellcome Sanger Institute.
- [4]